Publications by authors named "E J Sims"
Vaccinating care home staff is essential to protect vulnerable residents by reducing infection risks and creating a safer care environment. However, vaccine hesitancy amongst staff remains a challenge, particularly since the COVID-19 pandemic raised concerns about side effects and vaccination mandates. This study examines how the pandemic influenced flu vaccine hesitancy amongst UK care home staff.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated a glucose fraction that operates independently of insulin secretion in individuals positive for diabetes-related autoantibodies.
- It utilized data from two major trials, analyzing the relationship between the glucose response and insulin levels through linear regression.
- Findings revealed that this independent glucose fraction (iAUCGLU) significantly contributes to the rise in blood sugar levels in impaired glucose tolerance and is a stronger predictor for this condition than for type 1 diabetes (T1D).
Energetic activity for depression in young people aged 13-17 years: the READY feasibility RCT.
Health Technol Assess
December 2024
Article Synopsis
- The study aims to evaluate the feasibility of an exercise intervention for young people aged 13-17 with mild to moderate depression, comparing high-intensity exercise, low-intensity exercise, and social activities.
- Participants were recruited through mental health services and schools, with the intervention delivered over 12 weeks by trained professionals.
- Results showed a 71.4% retention rate and over 67% attendance, although only 14 participants were randomized from the initial referrals, indicating challenges in recruitment.
Introduction This guideline serves as an update to the 2022 International Society for Pediatric and Adolescent Diabetes (ISPAD) consensus guideline on staging for Type 1 Diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta cell function in those with Stage 3 T1D is included.
View Article and Find Full Text PDFAims/hypothesis: We aimed to analyse TrialNet Anti-CD3 Prevention (TN10) data using oral minimal model (OMM)-derived indices to characterise the natural history of stage 2 type 1 diabetes in placebo-treated individuals, to describe early metabolic responses to teplizumab and to explore the predictive capacity of OMM measures for disease-free survival rate.
Methods: OMM-estimated insulin secretion, sensitivity and clearance and the disposition index were evaluated at baseline and at 3, 6 and 12 months post randomisation in placebo- and teplizumab-treated groups, and, within each group, in slow- and rapid-progressors (time to stage 3 disease >2 or 2 years). OMM metrics were also compared with the standard AUC C-peptide.